A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | MicrobiomeTrials
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-01-27Est. Completion: 2029-07-02
Enrollment target: 1,046 participants
Locations
Banner MD Anderson Cancer Center ( Site 0165), Gilbert, Arizona, United States
Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167), Phoenix, Arizona, United States
The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona, United States
Providence Medical Foundation-Oncology ( Site 0168), Fullerton, California, United States
MemorialCare Health System - Long Beach Medical Center ( Site 9559), Long Beach, California, United States
Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos, California, United States
Cedars-Sinai Medical Center ( Site 0115), Los Angeles, California, United States
Pacific Hematology Oncology Associates ( Site 0131), San Francisco, California, United States
Lutheran Hospital - Cancer Centers of Colorado ( Site 0180), Golden, Colorado, United States
Clermont Oncology Center ( Site 0182), Clermont, Florida, United States
Bioresearch Partner ( Site 0157), Hialeah, Florida, United States
Orlando Health Cancer Institute ( Site 0169), Ocoee, Florida, United States
Mid Florida Hematology and Oncology Center ( Site 0172), Orange City, Florida, United States
Other microbiome trials you might be interested in
Recurrent Diffuse Large B-Cell LymphomaRecurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
This phase II trial tests how well odronextamab works before and after standard of care (SOC) chimeric antigen receptor …
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2201), Warsaw, Masovian Voivodeship, Poland
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 2210), Słupsk, Pomeranian Voivodeship, Poland
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2208), Gliwice, Silesian Voivodeship, Poland
Pratia Onkologia Katowice ( Site 2204), Katowice, Silesian Voivodeship, Poland
Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2205), Olsztyn, Warmian-Masurian Voivodeship, Poland
Unidade Local de Saude de Braga - Hospital de Braga ( Site 2306), Braga, Portugal
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 2308), Lisbon, Portugal
Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2302), Porto, Portugal
BRCR Global - Mayaguez ( Site 1003), Mayagüez, Puerto Rico
Auxilio Mutuo Cancer Center ( Site 1001), San Juan, Puerto Rico
Spitalul Clinic Colțea ( Site 2401), Bucharest, Bucharest, Romania
Institutul Oncologic Cluj ( Site 2404), Cluj-Napoca, Cluj, Romania
Centrul de Diagnostic si Tratament Oncologic Brasov ( Site 2402), Brasov, Romania
Spital Judetean Sibiu ( Site 2405), Sibiu, Romania
National University Hospital ( Site 3702), Singapore, Central Singapore, Singapore
National Cancer Centre Singapore ( Site 3701), Singapore, Central Singapore, Singapore
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 2506), Pretoria, Gauteng, South Africa
Netcare Pretoria East Hospital ( Site 2502), Pretoria, Gauteng, South Africa
Haemalife ( Site 2501), Cape Town, Western Cape, South Africa
Groote Schuur Hospital ( Site 2504), Cape Town, Western Cape, South Africa
National Cancer Center- Center for Hemotologic malignancy ( Site 3806), Goyang-si, Kyonggi-do, South Korea
Pusan National University Hospital ( Site 3804), Busan, Pusan-Kwangyokshi, South Korea
Chungnam National University Hospital ( Site 3801), Daejeon, Taejon-Kwangyokshi, South Korea
Severance Hospital, Yonsei University Health System ( Site 3802), Seoul, South Korea
Asan Medical Center ( Site 3803), Seoul, South Korea
Samsung Medical Center ( Site 3807), Seoul, South Korea
St.Mary's H., Youido ( Site 3805), Seoul, South Korea
Hospital Universitario Virgen Macarena ( Site 2608), Seville, Andalusia, Spain
ICO L Hospitalet ( Site 2601), L'Hospitalet de Llobregat, Barcelona, Spain
H. Insular de Gran Canaria ( Site 2606), Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario Puerta de Hierro ( Site 2615), Majadahonda, Madrid, Spain
Hospital General Universitario Dr. Balmis ( Site 2604), Alicante, Valenciana, Comunitat, Spain
Hospital del Mar ( Site 2610), Barcelona, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2614), Madrid, Spain
Hospital General Universitario 12 de Octubre ( Site 2605), Madrid, Spain
Hospital Universitario La Paz ( Site 2611), Madrid, Spain
Hospital Virgen de la Victoria ( Site 2609), Málaga, Spain
Hospital Universitario Miguel Servet ( Site 2607), Zaragoza, Spain
Kantonspital Baden ( Site 2703), Baden, Canton of Aargau, Switzerland
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 2702), Sankt Gallen, Canton of St. Gallen, Switzerland
Ospedale Regionale Bellinzona e Valli ( Site 2701), Bellinzona, Canton Ticino, Switzerland
Ospedale Italiano Lugano (OIL) ( Site 2705), Lugano, Canton Ticino, Switzerland
Chang Gung Memorial Hospital - Linkou Branch ( Site 3903), Taoyuan City, Taoyuan, Taiwan
Chang Gung Memorial Hospital at Kaohsiung ( Site 3905), Kaohsiung City, Taiwan
National Cheng Kung University Hospital ( Site 3902), Tainan, Taiwan
National Taiwan University Hospital ( Site 3901), Taipei, Taiwan
Mackay Memorial Hospital ( Site 3908), Taipei, Taiwan
Tri-Service General Hospital ( Site 3906), Taipei, Taiwan
Faculty of Medicine Siriraj Hospital ( Site 4001), Bangkoknoi, Bangkok, Thailand
Chulalongkorn University ( Site 4003), Pathumwan, Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 4002), Muang, Chiang Mai, Thailand
Ondokuz Mayıs Universitesi ( Site 2806), Korfez Mahallesi, Samsun, Turkey (Türkiye)
Namık Kemal University Medical Faculty ( Site 2807), Suleymanpasa, Tekirdas, Turkey (Türkiye)
Baskent Universitesi Adana Dr. Turgut Noyan UAM ( Site 2809), Adana, Turkey (Türkiye)
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 2803), Ankara, Turkey (Türkiye)
Hacettepe Universite Hastaneleri ( Site 2810), Ankara, Turkey (Türkiye)
Ankara University Faculty of Medicine ( Site 2801), Ankara, Turkey (Türkiye)
Antalya Egitim ve Arastirma Hastanesi ( Site 2805), Antalya, Turkey (Türkiye)
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi ( Site 2804), Istanbul, Turkey (Türkiye)
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2904), Cherkasy, Cherkasy Oblast, Ukraine
Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2906), Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Khmelnytskyi Regional Hospital ( Site 2907), Khmelnytskiy, Khmelnytskyi Oblast, Ukraine
Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903), Lviv, Lviv Oblast, Ukraine
SNPE National Cancer Institute ( Site 2902), Kyiv, Ukraine
Universal Clinic Oberig ( Site 2908), Kyiv, Ukraine
SI National Research Center of Radiation Medicine, Hematology, Oncology ( Site 2901), Kyiv, Ukraine
Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2905), Kyiv, Ukraine
Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedDouble-Expressor LymphomaEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsHigh Grade B-Cell Lymphoma, Not Otherwise SpecifiedNeoplastic Cells With Double Expression of MYC and BCL2 Proteins PresentTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or …
Birmingham, United StatesEst. completion Apr 1, 2028